Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
02/19/2021 02/22/2021 02/23/2021 02/24/2021 02/25/2021 Date
1215.2(c) 1205.4(c) 1214.8(c) 1213(c) 1216 Last
13 360 499 12 322 245 9 729 702 7 860 276 6 016 905 Volume
-1.92% -0.81% +0.78% -0.15% +0.25% Change
More quotes
Financials
Sales 2020 34 076 M 47 819 M 47 819 M
Net income 2020 4 894 M 6 868 M 6 868 M
Net Debt 2020 22 676 M 31 821 M 31 821 M
P/E ratio 2020 12,5x
Yield 2020 6,60%
Sales 2021 34 056 M 47 791 M 47 791 M
Net income 2021 3 474 M 4 874 M 4 874 M
Net Debt 2021 21 652 M 30 385 M 30 385 M
P/E ratio 2021 17,5x
Yield 2021 6,56%
Capitalization 60 694 M 85 740 M 85 173 M
EV / Sales 2020 2,45x
EV / Sales 2021 2,42x
Nbr of Employees 99 437
Free-Float 92,5%
More Financials
Company
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (52%): intended for respiratory diseases (67.5% of net sales), HIV infection (27.7%), immune system disorders (3.5%) ) and cancer (1,3%); - OTC and parapharmaceutical medicine (26.7%); - vaccines (21.2%); - other (0.1%). Net sales are distributed geographically as... 
Sector
Pharmaceuticals
Calendar
04/28Earnings Release
More about the company
Notations Surperformance© of GlaxoSmithKline plc
Trading Rating : Investor Rating :
More Ratings
All news about GLAXOSMITHKLINE PLC
05:10pGLAXOSMITHKLINE : Study on Otilimab for Treatment of Hospitalized Patients with ..
MT
02:52pGLAXOSMITHKLINE : Study on Otilimab for Treatment of Hospitalized Adult Patients..
MT
08:11aGLAXOSMITHKLINE : GSK to Assess Efficacy of COVID-19 Monoclonal Antibody Treatme..
MT
07:22aGSK narrows focus on elderly in trial to treat pneumonia from COVID-19
RE
07:14aGLAXOSMITHKLINE : Covid-19 Antibody Study Didn't Meet Primary Endpoint
DJ
07:06aGLAXOSMITHKLINE : GSK announces results evaluating its investigational monoclona..
PU
02/24GRANULES INDIA : Gets US FDA Nod For Migraine Treatment Drug
MT
02/24GLAXOSMITHKLINE : GSK Unit ViiV Seeks FDA Approval for Expanded Use of HIV-1 Inf..
MT
02/24GLAXOSMITHKLINE : ViiV Healthcare Seeks FDA Approval for Expanded Use of HIV-1 I..
MT
02/22GLAXOSMITHKLINE : GSK and Sanofi start with new COVID-19 vaccine study after set..
RE
02/22SANOFI : GlaxoSmithKline Initiate Phase 2 Study of COVID-19 Vaccine to Identify ..
MT
02/22GLAXOSMITHKLINE : GSK, Sanofi Begin Phase Two Of Protein-Based COVID-19 Vaccine ..
MT
02/22SANOFI : GSK Start New Covid-19 Vaccine Study After Setback
DJ
02/22GSK and Sanofi start with new COVID-19 vaccine study after setback
RE
02/22SANOFI : GSK Start New Phase 2 Study Of Adjuvanted Recombinant Protein-Based COV..
RE
More news
News in other languages on GLAXOSMITHKLINE PLC
10:51aGSK : résultats mitigés pour un traitement contre le Covid
08:42a40 femmes d’affaires qui comptent en Europe
07:21aGLAXOSMITHKLINE : Corona-Antikörper von GlaxosmithKline verfehlt Studienziel
02/23LONDON STOCK EXCHANGE : Coronavirus-Le Royaume-Uni recense 548 décès et 8.489 no..
02/23COVID-19 : jeu de chaises musicales dans l’industrie pharmaceutique
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 1 567,63 GBX
Last Close Price 1 213,00 GBX
Spread / Highest target 93,7%
Spread / Average Target 29,2%
Spread / Lowest Target -20,5%
EPS Revisions
Managers and Directors
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-9.61%85 313
JOHNSON & JOHNSON3.31%427 397
ROCHE HOLDING AG-2.09%285 788
NOVARTIS AG-5.12%197 223
ABBVIE INC.1.44%191 934
MERCK & CO., INC.-8.84%188 665